Astrazeneca Coronavirus Vaccine
- All
- News
- Videos
-
Covaxin Has Excellent Safety Record: Bharat Biotech On Study Citing Risks
The study, led by Banaras Hindu University (BHU), claimed that Covaxin raised the rare risk of stroke, and Guillain-Barre syndrome, among others.
-
Supreme Court Agrees To Hear Plea Over Covishield Side-Effect Concern
The Supreme Court will hear a petition on a rare side-effect associated with the COVID vaccine developed jointly by British pharma giant AstraZeneca and Oxford University, manufactured by the Serum Institute of India and sold in India as Covishield.
-
AstraZeneca Claims Positive Medicine Trial For "Severe" Covid
A treatment for people at risk of death from coronavirus has revealed good results in a late-stage trial, its maker AstraZeneca announced Wednesday.
-
Lancet Study On Covishield Vaccine Protection Decline Is Misquoted: Experts
The Lancet study, which reportedly states that the protection offered by the Oxford AstraZeneca COVID-19 vaccine Covishield declines after 3 months, has been misquoted, said experts.
-
On Omicron, AstraZeneca Says Booster Effective, Cites Oxford Lab Study
A three-dose course of AstraZeneca's COVID-19 vaccine is effective against the Omicron coronavirus variant, the pharmaceutical company said on Thursday, citing data from an Oxford University lab study.
-
Omicron vs Vaccines Shows What Scientists Fear In New Study
The omicron variant dented the protection afforded by two doses of Pfizer Inc.'s and AstraZeneca Plc's Covid vaccines as feared, researchers found, increasing the risk of infection.
-
Mixing Covid Vaccines Is Effective In Study on Pfizer, AstraZeneca
Mixing other vaccines with those from AstraZeneca Plc or Pfizer Inc. offers at least as effective protection against Covid-19 as giving two doses of the same shots, a UK study found.
-
Britain's Prince Charles To Open New AstraZeneca Research Centre
Britain's Prince Charles will formally open a new 1 billion pound AstraZeneca research and development (R&D) facility on Tuesday, as the company aims to fuel the growth of its drug pipeline.
-
Covid Poses Higher Risk Of Rare Brain Conditions Than Vaccines: Oxford-Led Study
COVID-19 is more likely to cause very rare neurological conditions than vaccination with the AstraZeneca or Pfizer preventives, according to a study led by the University of Oxford in the UK.
-
Covishield, China's Sinovac Approved By Australia Ahead Of Border Opening
Australia recognized China's Sinovac Biotech Ltd. COVID-19 shot and India-made AstraZeneca Plc jabs, paving the way for overseas travelers and fee-paying foreign students who have received those vaccinations to enter the country.
-
Nerve Disorder Listed As "Very Rare" Side Effect Of AstraZeneca Vaccine
The European Medicines Agency has listed the neurological disorder Guillain-Barre syndrome, which can cause temporary paralysis, as a "very rare" side effect of the AstraZeneca Covid-19 vaccine.
-
European Union, AstraZeneca Settle Vaccine Supply Dispute Out Of Court
The European Union and UK-based drugs giant AstraZeneca announced Friday that they had reached a settlement in a dispute over a shortfall in coronavirus vaccine deliveries.
-
COVID-19 Has More Blood Clot Threat Than Vaccines, Says UK Study: Report
A coronavirus infection presents a much higher risk of developing a blood clot than the first dose of either the Oxford/AstraZeneca or the Pfizer/BioNTech jab, a large study led by the University of Oxford said on Friday.
-
Protection From Pfizer, AstraZeneca Jabs Wanes Within 6 Months: UK Study
Protection against COVID-19 offered by two doses of the Pfizer/BioNTech and the Oxford/AstraZeneca coronavirus vaccines begins to fade within six months, underscoring the need for booster shots, according to researchers in Britain.
-
Clotting Linked With AstraZeneca Vaccine Very Rare, Says Oxford Study
The very rare blood clots that can be caused by the Oxford/AstraZeneca coronavirus vaccine can be aggressive and deadly but is very rare, leading scientists have concluded in the findings of the first study of its kind on Thursday.
-
Covaxin Has Excellent Safety Record: Bharat Biotech On Study Citing Risks
The study, led by Banaras Hindu University (BHU), claimed that Covaxin raised the rare risk of stroke, and Guillain-Barre syndrome, among others.
-
Supreme Court Agrees To Hear Plea Over Covishield Side-Effect Concern
The Supreme Court will hear a petition on a rare side-effect associated with the COVID vaccine developed jointly by British pharma giant AstraZeneca and Oxford University, manufactured by the Serum Institute of India and sold in India as Covishield.
-
AstraZeneca Claims Positive Medicine Trial For "Severe" Covid
A treatment for people at risk of death from coronavirus has revealed good results in a late-stage trial, its maker AstraZeneca announced Wednesday.
-
Lancet Study On Covishield Vaccine Protection Decline Is Misquoted: Experts
The Lancet study, which reportedly states that the protection offered by the Oxford AstraZeneca COVID-19 vaccine Covishield declines after 3 months, has been misquoted, said experts.
-
On Omicron, AstraZeneca Says Booster Effective, Cites Oxford Lab Study
A three-dose course of AstraZeneca's COVID-19 vaccine is effective against the Omicron coronavirus variant, the pharmaceutical company said on Thursday, citing data from an Oxford University lab study.
-
Omicron vs Vaccines Shows What Scientists Fear In New Study
The omicron variant dented the protection afforded by two doses of Pfizer Inc.'s and AstraZeneca Plc's Covid vaccines as feared, researchers found, increasing the risk of infection.
-
Mixing Covid Vaccines Is Effective In Study on Pfizer, AstraZeneca
Mixing other vaccines with those from AstraZeneca Plc or Pfizer Inc. offers at least as effective protection against Covid-19 as giving two doses of the same shots, a UK study found.
-
Britain's Prince Charles To Open New AstraZeneca Research Centre
Britain's Prince Charles will formally open a new 1 billion pound AstraZeneca research and development (R&D) facility on Tuesday, as the company aims to fuel the growth of its drug pipeline.
-
Covid Poses Higher Risk Of Rare Brain Conditions Than Vaccines: Oxford-Led Study
COVID-19 is more likely to cause very rare neurological conditions than vaccination with the AstraZeneca or Pfizer preventives, according to a study led by the University of Oxford in the UK.
-
Covishield, China's Sinovac Approved By Australia Ahead Of Border Opening
Australia recognized China's Sinovac Biotech Ltd. COVID-19 shot and India-made AstraZeneca Plc jabs, paving the way for overseas travelers and fee-paying foreign students who have received those vaccinations to enter the country.
-
Nerve Disorder Listed As "Very Rare" Side Effect Of AstraZeneca Vaccine
The European Medicines Agency has listed the neurological disorder Guillain-Barre syndrome, which can cause temporary paralysis, as a "very rare" side effect of the AstraZeneca Covid-19 vaccine.
-
European Union, AstraZeneca Settle Vaccine Supply Dispute Out Of Court
The European Union and UK-based drugs giant AstraZeneca announced Friday that they had reached a settlement in a dispute over a shortfall in coronavirus vaccine deliveries.
-
COVID-19 Has More Blood Clot Threat Than Vaccines, Says UK Study: Report
A coronavirus infection presents a much higher risk of developing a blood clot than the first dose of either the Oxford/AstraZeneca or the Pfizer/BioNTech jab, a large study led by the University of Oxford said on Friday.
-
Protection From Pfizer, AstraZeneca Jabs Wanes Within 6 Months: UK Study
Protection against COVID-19 offered by two doses of the Pfizer/BioNTech and the Oxford/AstraZeneca coronavirus vaccines begins to fade within six months, underscoring the need for booster shots, according to researchers in Britain.
-
Clotting Linked With AstraZeneca Vaccine Very Rare, Says Oxford Study
The very rare blood clots that can be caused by the Oxford/AstraZeneca coronavirus vaccine can be aggressive and deadly but is very rare, leading scientists have concluded in the findings of the first study of its kind on Thursday.
